Anti-Wilms Tumor Protein Antibody, clone 2O18 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2O18 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Wilms Tumor Protein (WT33). It targets an epitope within 23 amino acids from the N-terminal half.

KLH-conjugated linear peptide corresponding to 23 amino acids from the N-terminal half of human Wilms Tumor Protein.

Quality Control Testing

Evaluated by Western Blotting in HEK293 cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected Wilms Tumor Protein in HEK293 cell lysate.

Tested applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected Wilms Tumor Protein in OVCAR-3 cell lysate.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Wilms Tumor Protein (WT33) in OVCAR-3 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Wilms Tumor Protein (WT33) in human kidney tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Wilms tumor protein (UniProt: P19544; also known as WT33) is encoded by the WT1 gene (Gene ID: 7490) in human. It serves as a transcription factor that plays an important role in cellular development and cell survival. It is expressed in the kidney and a subset of hematopoietic cells. It regulates the expression of numerous target genes, including EPO. Wilms tumor protein plays an essential role for development of the urogenital system and has a tumor suppressor as well as an oncogenic role in tumor formation. Eight different isoforms of Wilms tumor protein have been described that are produced by alternative splicing. Isoforms lacking the KTS motif act as transcription factors while isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA and can bind RNA. The N-terminal region of Wilms tumor protein contains a proline-rich region (aa 27-83) involved in transcriptional regulation, self-association, and RNA recognition, while its C-terminal region contains four C2H2-type zinc fingers (aa 323-347, 353-377, 383-405, 414-438) that mediate DNA and RNA binding. Its zinc finger domain can bind to GC-rich sequences, such as the EGR-1 consensus sequence (5 -GCG(T/G)GGGCG-3 ), the WTE motif (5′-GCGTGGGAGT-3′), or (TCC)n motif. Mutations in WT1 gene are reported to cause Wilms tumors characterized by embryonal malignancy of the kidney. Some mutations are reported to cause nephrotic syndrome 4, which causes severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.